-
公开(公告)号：US08377438B2
公开(公告)日：2013-02-19
申请号：US13331145
申请日：2011-12-20
申请人： Yue Yao , Janine Bilsborough
发明人： Yue Yao , Janine Bilsborough
IPC分类号： A61K39/395 , A61K38/00 , C07K16/28 , C07K14/435 , C07K14/00
CPC分类号： C07K16/244 , A61K38/1793 , A61K39/3955 , A61K2039/505 , C07K16/2866 , C07K2317/14 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/76
摘要： Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
摘要翻译： 使用拮抗剂IL-31用于通过抑制，预防，减少，最小化，限制或最小化神经元组织中的刺激来治疗炎症和疼痛。 这样的拮抗剂包括抗体及其片段，衍生物或变体。 症状如疼痛，刺痛，致敏，与神经病相关的痒症得到改善。
-
22.发明授权Methods of treating multiple sclerosis (MS) using an IL-17A and IL-17F antagonist 有权使用IL-17A和IL-17F拮抗剂治疗多发性硬化（MS）的方法公开(公告)号：US08268773B2
公开(公告)日：2012-09-18
申请号：US13015304
申请日：2011-01-27
申请人： Scott R. Presnell , Steven K. Burkhead , Steven D. Levin , Rolf E. Kuestner , Zeren Gao , Stephen R. Jaspers , Janine Bilsborough
发明人： Scott R. Presnell , Steven K. Burkhead , Steven D. Levin , Rolf E. Kuestner , Zeren Gao , Stephen R. Jaspers , Janine Bilsborough
IPC分类号： A61K38/00
CPC分类号： C07K16/2866 , A61K2039/505 , C07K14/7155 , C07K2317/73 , C07K2317/76 , C07K2319/30
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.
摘要翻译： 本发明涉及阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者多肽分子的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 ZcytoR14是IL-17A和IL-17F的常见受体。 本发明包括可溶性ZcytoR14，抗ZcytoR14抗体和结合配偶体，以及使用这种可溶性受体，抗体和结合配偶体拮抗IL-17F，IL-17A或IL-17A和IL-17F两者的方法。
-
公开(公告)号：US20120219540A1
公开(公告)日：2012-08-30
申请号：US13417587
申请日：2012-03-12
申请人： Zeren Gao , Steven D. Levin , Janine Bilsborough , James W. West , Cameron S. Brandt , Eric M. Chadwick
发明人： Zeren Gao , Steven D. Levin , Janine Bilsborough , James W. West , Cameron S. Brandt , Eric M. Chadwick
IPC分类号： A61K38/17 , G01N33/566 , A61K31/7105 , A61P37/00 , A61K39/395 , A61K31/713
CPC分类号： C07K16/2827 , A61K38/00 , A61K2039/507 , C07K14/47 , C07K14/70532 , C07K16/2803 , C07K16/2818 , C07K2317/34 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2319/00 , C07K2319/30 , C12Q1/66 , G01N33/505 , G01N33/56972 , G01N2333/70532
摘要： The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.
摘要翻译： 本发明提供新鉴定的B7受体，作为淋巴细胞抑制性受体的zB7R1，其是PD-1样分子，并在T细胞上表达。 本发明还提供了zB7R1与CD155结合的能力的发现。 还提供了用于调节zB7R1介导的负信号并干扰其反受体相互作用用于治疗，诊断和研究目的的方法和组合物。
-
24.发明授权Antagonizing signal transduction in dorsal root ganglion cells in a subject with IL-31 antagonists 有权IL-31拮抗剂受试者背根神经节细胞的拮抗信号转导公开(公告)号：US07939068B2
公开(公告)日：2011-05-10
申请号：US12395095
申请日：2009-02-27
申请人： Yue Yao , Janine Bilsborough
发明人： Yue Yao , Janine Bilsborough
IPC分类号： A61K39/395 , A61K38/00 , C07K16/28 , C07K14/435 , C07K14/00
CPC分类号： C07K16/244 , A61K38/1793 , A61K39/3955 , A61K2039/505 , C07K16/2866 , C07K2317/14 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/76
摘要： Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
摘要翻译： 使用拮抗剂IL-31用于通过抑制，预防，减少，最小化，限制或最小化神经元组织中的刺激来治疗炎症和疼痛。 这样的拮抗剂包括抗体及其片段，衍生物或变体。 症状如疼痛，刺痛，致敏，与神经病相关的痒症得到改善。
-
25.发明申请ANTAGONIZING SIGNAL TRANSDUCTION IN DORSAL ROOT GANGLION CELLS IN A SUBJECT WITH IL-31 ANTAGONISTS 有权拮抗IL-31拮抗剂的脊髓背根神经节细胞信号转导公开(公告)号：US20100221244A1
公开(公告)日：2010-09-02
申请号：US12395095
申请日：2009-02-27
申请人： Yue Yao , Janine Bilsborough
发明人： Yue Yao , Janine Bilsborough
IPC分类号： A61K39/395 , A61P25/00
CPC分类号： C07K16/244 , A61K38/1793 , A61K39/3955 , A61K2039/505 , C07K16/2866 , C07K2317/14 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/76
摘要： Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
摘要翻译： 使用拮抗剂IL-31用于通过抑制，预防，减少，最小化，限制或最小化神经元组织中的刺激来治疗炎症和疼痛。 这样的拮抗剂包括抗体及其片段，衍生物或变体。 症状如疼痛，刺痛，致敏，与神经病相关的痒症得到改善。
-
26.发明申请METHODS OF TREATING DISEASES WHICH ARE MEDIATED BY CUTANEOUS LYMPHOCYTE ANTIGEN POSITIVE CELLS 审中-公开治疗由丁香球蛋白抗原阳性细胞介导的疾病的方法公开(公告)号：US20090280121A1
公开(公告)日：2009-11-12
申请号：US12497383
申请日：2009-07-02
IPC分类号： A61K39/395 , A61P17/00 , A61P17/02 , A61P17/10
CPC分类号： C07K16/244 , A61K39/3955 , A61K49/0008 , A61K49/006 , A61K2039/505 , A61K2039/545 , C07K14/52 , C07K16/2803 , C07K2317/76 , G01N33/505 , G01N33/6869 , G01N33/6881
摘要： The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous T cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, and herpes simplex virus, or combination thereof will benefit from the administration of an IL-31 antagonist. The invention also includes methods of predicting a therapeutically responsive patient population.
摘要翻译： 本发明涉及治疗患有由皮肤淋巴细胞抗原阳性T细胞介导的瘙痒和精神炎的患者的方法。 特别是，包括接触性皮炎，药物诱发的延迟型皮肤过敏反应，中毒性表皮坏死松解症，皮肤T细胞淋巴瘤，大疱性类天疱疮，秃头症，白癜风，痤疮性红斑痤疮，结节性痤疮，单纯疱疹病毒或其组合的疾病或病症， 受益于IL-31拮抗剂的给药。 本发明还包括预测治疗响应的患者群体的方法。
-
27.发明申请METHODS OF TREATING PAIN AND INFLAMMATION IN NEURONAL TISSUE USING IL-31 ANTAGONISTS 有权使用IL-31拮抗剂治疗神经组织疼痛和炎症的方法公开(公告)号：US20070160610A1
公开(公告)日：2007-07-12
申请号：US11621829
申请日：2007-01-10
申请人： Yue Yao , Janine Bilsborough , Cecile Krejsa , Linda Zuckerman , Mark Rogge
发明人： Yue Yao , Janine Bilsborough , Cecile Krejsa , Linda Zuckerman , Mark Rogge
IPC分类号： A61K39/395
CPC分类号： C07K16/244 , A61K38/1793 , A61K39/3955 , A61K2039/505 , C07K16/2866 , C07K2317/14 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/76
摘要： Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
摘要翻译： 使用拮抗剂IL-31用于通过抑制，预防，减少，最小化，限制或最小化神经元组织中的刺激来治疗炎症和疼痛。 这样的拮抗剂包括抗体及其片段，衍生物或变体。 症状如疼痛，刺痛，致敏，与神经病相关的痒症得到改善。
-
公开(公告)号：US20070054360A1
公开(公告)日：2007-03-08
申请号：US11433276
申请日：2006-05-12
申请人： Zeren Gao , Steven Levin , Janine Bilsborough , James West , Cameron Brandt , Frederick Ramsdell , Edward Howard , Erick Chadwick
发明人： Zeren Gao , Steven Levin , Janine Bilsborough , James West , Cameron Brandt , Frederick Ramsdell , Edward Howard , Erick Chadwick
IPC分类号： C12P21/06 , C07H21/04 , C07K14/705 , C07K16/30
CPC分类号： C07K16/2827 , A61K38/00 , A61K2039/507 , C07K14/47 , C07K14/70532 , C07K16/2803 , C07K16/2818 , C07K2317/34 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2319/00 , C07K2319/30 , C12Q1/66 , G01N33/505 , G01N33/56972 , G01N2333/70532
摘要： The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.
摘要翻译： 本发明提供新鉴定的B7受体，作为淋巴细胞抑制性受体的zB7R1，其是PD-1样分子，并在T细胞上表达。 本发明还提供了zB7R1与CD155结合的能力的发现。 还提供了用于调节zB7R1介导的负信号并干扰其反受体相互作用用于治疗，诊断和研究目的的方法和组合物。
-
29.发明申请SOLUBLE ZCYTOR14, ANTI-ZCYTOR14 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION 审中-公开可溶性ZCYTOR14抗体ZIYTOR14抗体和结合合作伙伴及其使用方法公开(公告)号：US20070048826A1
公开(公告)日：2007-03-01
申请号：US11538574
申请日：2006-10-04
申请人： Scott Presnell , Steven Burkhead , Steven Levin , Rolf Kuestner , Zeren Gao , Stephen Jaspers , Janine Bilsborough
发明人： Scott Presnell , Steven Burkhead , Steven Levin , Rolf Kuestner , Zeren Gao , Stephen Jaspers , Janine Bilsborough
IPC分类号： A61K38/17 , C07K14/715 , C07H21/04 , C12P21/06
CPC分类号： C07K16/2866 , A61K2039/505 , C07K14/7155 , C07K2317/73 , C07K2317/76 , C07K2319/30
摘要： The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.
摘要翻译： 本发明涉及阻断，抑制，减少，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者多肽分子的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 ZcytoR14是IL-17A和IL-17F的常见受体。 本发明包括可溶性ZcytoR14，抗ZcytoR14抗体和结合配偶体，以及使用这种可溶性受体，抗体和结合配偶体拮抗IL-17F，IL-17A或IL-17A和IL-17F两者的方法。
-
公开(公告)号：US20120207757A1
公开(公告)日：2012-08-16
申请号：US13332758
申请日：2011-12-21
申请人： Yue Yao , Janine Bilsborough
发明人： Yue Yao , Janine Bilsborough
IPC分类号： A61K39/395
CPC分类号： C07K16/244 , A61K38/1793 , A61K39/3955 , A61K2039/505 , C07K16/2866 , C07K2317/14 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/76
摘要： Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
摘要翻译： IL-31Ra和OSMRb的拮抗剂的使用用于通过抑制，预防，减少，最小化，限制或最小化神经元组织中的刺激来治疗炎症和疼痛。 这样的拮抗剂包括可溶性受体，抗体及其片段，衍生物或变体。 症状如疼痛，刺痛，致敏，与神经病相关的痒症得到改善。
-
-
-
-
-
-
-
-
-
搜索结果
47 条记录 (耗时 0.049 秒)
